¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (1ÀÏÂ÷) : 2022-10-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (1ÀÏÂ÷) : 2022-10-15
±³À°ÀÏÀÚ : 2022-10-15
±³À°Àå¼Ò : ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï ÄÚ¿¢½º Çϸð´Ïº¼·ë ¿Ü  
±³À°ÁÖÁ¦ : 2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ´ëÇÑÇǺΰúÇÐȸ
¿¬¶ôó : 02-3473-0284  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 19 ½Ã°£ 19ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í Á¤È¸¿ø 80,000 / ÁØȸ¿ø 40,000 / ºñȸ¿ø 500,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10-15 Harmony 1+2 08:00~08:03 1. Introduction  Chair() 
±³À°½Ã°£ 10-15 Harmony 1+2 08:03~08:48 2. Real world evidence of biologics for PsO and clinical experience  Dr. Melinda Gooderham(Skin health Canada) 
Åä·Ð 10-15 Harmony 1+2 08:48~09:00 3. Q&A  () 
±³À°½Ã°£ 10-15 Vivace 09:00~09:12 1. The effect of particulate matter in Demodex-induced immunomodulation of skin  ±èÁöÈñ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 09:12~09:24 2. The role of tumor suppressor gene WWOX in skin inflammation via PKC and NF-kB signaling pathway  ±èÁ¤Àº(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 09:24~09:36 3. A study on the effect of particulate matter on acne  ¹Ú±Í¿µ(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 09:36~09:48 4. Investigation of the association between dermatologic disorders and the first exposure to general anesthesia using istrative healthcare databases  ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 09:48~10:00 5. Establishment of vitiligo mouse model using transgenic mouse  ÃÖÁ¾¿ø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-15 Allegro 08:30~08:45 Overview and introduction of board exam  Examination Committee() 
±³À°½Ã°£ 10-15 Allegro 08:45~09:10 1. Keratinization, barrier development and skin immune system  ½ÅÇöÅÂ(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 10-15 Allegro 09:10~09:35 2. Atopic dermatitis, contact dermatitis, seborrheic dermatitis, and other eczematous dermatitis  ½Å±âÇõ(ºÎ»êÀÇ´ë) 
È޽Ġ10-15 Allegro 09:35~09:40 Break  () 
±³À°½Ã°£ 10-15 Allegro 09:40~10:05 3. Bacterial and fungal infection  ¼­Çö¹Î(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 10-15 Allegro 10:05~10:25 4. Viral and other infection  Áֹμ÷(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 10-15 Allegro 10:25~10:45 5. Dermatopathology  ¹ÚÁöÇý(¼º±Õ°üÀÇ´ë) 
È޽Ġ10-15 Allegro 10:45~10:50 Break  () 
±³À°½Ã°£ 10-15 Allegro 10:50~11:15 6. Papulosquamous disease  ±èűÕ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-15 Allegro 11:15~11:30 7. Mucosal and adnexal disease  Á¤ÀÇÇö(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 10:00~10:25 1. Non-dermatological itching exacerbated by scratching  ±èÇý¿ø(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 10:25~10:50 2. A look into the skin microbiome in chronic scratch lesions  ±èÇý¼º(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 10:50~11:15 3. Journey with the expert researchers into melanocyte biology and pigmentary diseases  À̽ÃÇü(¼­¿ïÀÇ´ë) 
Åä·Ð 10-15 Vivace 11:15~11:30 4. Q&A  () 
±âŸ 10-15 Harmony 3 10:30~10:35 1. Introduction  Chair() 
±³À°½Ã°£ 10-15 Harmony 3 10:35~10:55 2-1. Atopic dermatitis: A personal disease with individual needs  ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø) 
±³À°½Ã°£ 10-15 Harmony 3 10:55~11:15 2-2. Addressing individual needs and tailored approaches to the treatment of patients with AD  ³ªÂùÈ£(Á¶¼±ÀÇ´ë) 
Åä·Ð 10-15 Harmony 3 11:15~11:30 3. Q&A  () 
±³À°½Ã°£ 10-15 Allegro 14:00~14:05 1. Introduction  Chair() 
±³À°½Ã°£ 10-15 Allegro 14:05~14:25 2-1. Time to be LiMMitless: The SKY is the limit for psoriasis treatment  Á¶¼ºÁø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-15 Allegro 14:25~14:45 2-2. Time to be obJAKtive: JAKi  °íÇöâ(ºÎ»êÀÇ´ë) 
Åä·Ð 10-15 Allegro 14:45~15:00 3. Q&A  () 
±³À°½Ã°£ 10-15 Harmony 1+2 11:30~11:33 1. Introduction  Chair() 
±³À°½Ã°£ 10-15 Harmony 1+2 11:33~12:18 2. Drug survival associated with effectiveness and safety of treatment with guselkumab  Alexander Egeberg(Copenhagen University Hospital Denmark) 
Åä·Ð 10-15 Harmony 1+2 12:18~12:30 3. Q&A  () 
±âŸ 10-15 Harmony 1+2 13:10~13:15 1. Introduction  ±èÀ¯Âù(´ëÇÑÇǺΰúÇÐȸ ȸÀå) 
±³À°½Ã°£ 10-15 Harmony 1+2 13:15~13:30 2. Herpes zoster  ÀÌÁøŹ(ÀÌÁøŹÇǺΰú) 
±âŸ 10-15 Harmony 1+2 13:30~13:35 1. Introduction  () 
±³À°½Ã°£ 10-15 Harmony 1+2 13:35~13:55 2. First metastasis of acral melanoma: Role of pigmentation  À±¼÷Á¤(Àü³²ÀÇ´ë) 
Åä·Ð 10-15 Harmony 1+2 13:55~14:00 3. Q&A  () 
±³À°½Ã°£ 10-15 Harmony 1+2 14:00~14:50 1. Alopecia areata updates  ½É¿ì¿µ(°æÈñÀÇ´ë) 
Åä·Ð 10-15 Harmony 1+2 14:50~15:00 2. Q&A  () 
±âŸ 10-15 Harmony 3 14:00~14:03 1. Overview  Chair() 
±³À°½Ã°£ 10-15 Harmony 3 14:03~14:15 2. Physical signs of the nail unit  Á¤ÇýÁ¤(±¹¸³Áß¾ÓÀÇ·á¿ø) 
±³À°½Ã°£ 10-15 Harmony 3 14:15~14:27 3. Nail changes by contact materials  À̽ÂÈ£(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 14:27~14:39 4. Non-melanocytic tumors of the nail unit  ¹®Á¦È£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 14:39~14:51 5. Nail biopsy  ¹ÚÁöÇý(¼º±Õ°üÀÇ´ë) 
Åä·Ð 10-15 Harmony 3 14:51~15:00 6. Q&A  () 
±³À°½Ã°£ 10-15 Harmony 3 15:30~15:35 1. Overview  Chair() 
±³À°½Ã°£ 10-15 Harmony 3 15:35~15:50 2. Introduction to hair biology  ¹ÚÇö¼±(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 15:50~16:05 3. Molecular dissection of hair structures with single cell sequencing  ±èµµ¿µ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 16:05~16:20 4. Genetic prediction of alopecia  ½ÅÇöÅÂ(ÀÎÇÏÀÇ´ë) 
Åä·Ð 10-15 Harmony 3 16:20~16:30 5. Q&A  () 
±³À°½Ã°£ 10-15 Vivace 14:00~14:17 1. Confusing skin disease: MF, CTCL vs. Atopic dermatitis  ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø) 
±³À°½Ã°£ 10-15 Vivace 14:17~14:34 2. Challenging clinical cases: Not an easy one  ÀÌ¿ìÁø(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 14:34~14:51 3. Selection of interesting or educative cases CME  ÀÌÁöÇý(°¡Å縯ÀÇ´ë) 
Åä·Ð 10-15 Vivace 14:51~15:00 4. Q&A  () 
±³À°½Ã°£ 10-15 Vivace 15:30~15:47 1. Pathogenesis  À强Àº(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 15:47~16:04 2. Assessment of high-risk patients for PIH  ³ªÁ¤ÀÓ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 16:04~16:21 3. Prevention & treatment  ±èÁ¤Àº(ÇѾçÀÇ´ë) 
Åä·Ð 10-15 Vivace 16:21~16:30 4. Q&A  () 
±³À°½Ã°£ 10-15 Vivace 16:30~16:47 1. Chronic inflammatory dermatosis  ±èÇöÁ¤(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 16:47~17:04 2. Acne and rosacea  Á¶¼Ò¿¬(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-15 Vivace 17:04~17:21 3. Aging skin  ÃÖÀÀÈ£(¿¬¼¼¿øÁÖÀÇ´ë) 
Åä·Ð 10-15 Vivace 17:21~17:30 4. Q&A  () 
±³À°½Ã°£ 10-15 Harmony 1+2 15:30~15:35 1. Introduction  Chair() 
±³À°½Ã°£ 10-15 Harmony 1+2 15:35~16:20 2. How did ex-Hansen patients survive in modern Korea: Visiting and recording sites related to ex-Hansen patients  ±è½Ã´ö(¹®ÇåÇÐÀÚ) 
Åä·Ð 10-15 Harmony 1+2 16:20~16:30 3. Q&A  () 
±³À°½Ã°£ 10-15 Harmony 1+2 16:30~16:42 1. The role of IL-17 in the pathogenesis of PsO & PsA  Á¤±âÇå(°æÈñÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 1+2 16:42~16:54 2. IL-17 blocker: Secukinumab  ±èűÕ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 1+2 16:54~17:06 3. IL-17 blocker: Ixekizumab  ¹æöȯ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 1+2 17:06~17:18 4. IL-17 blocker: Others (brodalumab, bimekizumab)  ¹éÀ¯»ó(°í·ÁÀÇ´ë) 
Åä·Ð 10-15 Harmony 1+2 17:18~17:30 5. Q&A  () 
±³À°½Ã°£ 10-15 Harmony 3 16:30~16:40 1. A 94-year-old woman with a rapidly growing erythematous tumor on the right cheek  ±èµ¿Çö(Â÷ÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 16:40~16:50 2. Hyperkeratotic erythematous plaque on the right temple in a 76-year-old man  ÇÏ´ë·æ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 16:50~17:00 3. Indurated, ill-defined patches with telangiectasia on both thighs in a 51-year-old female patient  ÀÌ¿ìÁø(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 17:00~17:10 4. Progressively enlarging erythematous-to-brownish sclerotic plaque on the back  ¹®Á¦È£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 17:10~17:20 5. Multiple variable sized hard painful erythematous nodules and pustules on trunk and extremities  Ãֹ̼ö(´Ü±¹ÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 17:20~17:30 6. Grouped annular erythematous eruption with vesicles and pustules on the trunk on a 27-year-old male  ±èÁöÈñ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 17:30~17:40 7. A firm lump on the flank of a 6-year-old boy  ¹ÚÁöÇì(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10-15 Harmony 3 17:40~17:50 8. Asymptomatic diffuse brownish to black patches and tumors in a 57-year-old woman  À±¼÷Á¤(Àü³²ÀÇ´ë) 
Åä·Ð 10-15 Harmony 3 17:50~18:00 9. Q&A  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (1ÀÏÂ÷) : 2022-10-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦18Â÷ °í¾ç.ÆÄÁÖ.±èÆ÷½ÃÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2022-10-15
´ÙÀ½±Û ´ëÇÑ°¡Á¤ÀÇÇÐȸ ÀüºÏÁöȸ Ã߰迬¼ö°­Á : 2022-10-15
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 50 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 36 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 38 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 48 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 39 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 32 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 13 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 13 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 30 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 15 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 14 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 34 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 24 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 30 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 23 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷